For the first time since the 1970's, a small group of Canadians have been granted (federal) permission to legally use psilocybin for medicinal purposes.
Exploring the companies and themes that make up this emerging and exciting new sector
MindMed Adds Psychedelic Assisted Therapy Expert Dr. Peter Gasser As Clinical Advisor For Project Lucy
MindMed adds a psychedelics therapy expert to its LSD research program.
4 Palliative Canadians approved for end of life psilocybin therapy through section 56(1) ; First legal medical exemptions for psilocybin in Canada since 1970s
LEGAL use of psilocybin in Canada for the first time in nearly 50 years.
Big Pharma: Friend or Foe of Psychedelic Drugs?
Big Pharma has strong incentives to embrace psychedelics. But will its predatory business model turn drug companies against these drugs?
Palliative Canadians endure punishing waits while Health Minister delays approval of Psilocybin mushrooms; TheraPsil expands effort to Ontario
More pressure on Ottawa to move forward on legalization of psilocybin.
Numinus and Together We Can Partner to Support Addiction Recovery and Mental Wellness
Numinus establishes a partnership with one of Canada's largest addiction treatment organizations.
MindMed Completes Dosing 18-MC Phase 1 Study
MindMed completes its Phase 1 study of its non-hallucinogenic formulation of ibogaine.
Mydecine Building Its Psychedelics Footprint
Mydecine Innovations Group has been building momentum with a string of recent announcements.
Psychedelics Investing 101: Creating a Basket of Psychedelics Stocks
Intelligent diversification is the key to investing in this emerging industry.
Are Psychedelics The Answer For Addiction?
Globally, over 1 billion people are substance abusers. The U.S. addiction treatment market is already a $35 billion per year industry. Psychedelic drugs may be the (better) answer.
The Lundquist Institute Accepts a $1.75 Million Anonymous Donation to Improve the Quality of Dying
Funding to evaluate the potential of psilocybin to ease end-of-life distress.
Numinus Announces Short Form Prospectus Offering of Units for Gross Proceeds of Up To $4.05 Million
Numinus is pricing its financing at CAD$0.27 per unit, with warrants priced at CAD$0.40.